Hong Kong stock market anomaly | Stone Pharmaceutical Group (01093.HK) rose over 4%, its ADC new drug again received FDA fast-track qualification, and JMT106 received approval for clinical trials in China.

According to the Zhixin Finance and Economics APP, China National Pharmaceutical Group (01093.HK) has risen by over 4% again, as of the time of writing, the increase is 3.81%, closing at 6.54 Hong Kong dollars, with a trading volume of 8.59 billion Hong Kong dollars.